Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance
April 06, 2015 at 16:01 PM EDT
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that the European Medicines Agency (EMA) has informed the Company, through ...